348 related articles for article (PubMed ID: 32189364)
61. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
62. [Dynamics of hepatitis B virus covalently closed circular DNA after serum virology response].
Li FF; Ren WH; Ding GH; Shi J; Han GQ
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):167-70. PubMed ID: 19335976
[TBL] [Abstract][Full Text] [Related]
63. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
[TBL] [Abstract][Full Text] [Related]
64. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
[TBL] [Abstract][Full Text] [Related]
65. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.
Huang YW; Takahashi S; Tsuge M; Chen CL; Wang TC; Abe H; Hu JT; Chen DS; Yang SS; Chayama K; Kao JH
Antivir Ther; 2015; 20(4):369-75. PubMed ID: 24739420
[TBL] [Abstract][Full Text] [Related]
66. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
67. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
Lai HW; Chang CC; Chen TH; Tsai MC; Chen TY; Lin CC
J Formos Med Assoc; 2012 Aug; 111(8):439-44. PubMed ID: 22939662
[TBL] [Abstract][Full Text] [Related]
68. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.
Matsuzaki T; Tatsuki I; Otani M; Akiyama M; Ozawa E; Miuma S; Miyaaki H; Taura N; Hayashi T; Okudaira S; Takatsuki M; Isomoto H; Takeshima F; Eguchi S; Nakao K
J Gastroenterol Hepatol; 2013 Jul; 28(7):1217-22. PubMed ID: 23432697
[TBL] [Abstract][Full Text] [Related]
69. Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients.
Chen S; Jia J; Gao Y; Li H; Fang M; Feng H; Guan W; Ji J; Gao Z; Gao C
Clin Chim Acta; 2018 Nov; 486():237-244. PubMed ID: 30025756
[TBL] [Abstract][Full Text] [Related]
70. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
Gu EL; Yu YQ; Wang JL; Ji YY; Ma XY; Xie Q; Pan HY; Wu SM; Li J; Chen CW; Xu XW; Wang YE; Yao GB; Wang H; Zhang WH
World J Gastroenterol; 2015 Jan; 21(2):653-60. PubMed ID: 25605989
[TBL] [Abstract][Full Text] [Related]
71. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.
Ahmed M; Wang F; Levin A; Le C; Eltayebi Y; Houghton M; Tyrrell L; Barakat K
Drug Discov Today; 2015 May; 20(5):548-61. PubMed ID: 25622780
[TBL] [Abstract][Full Text] [Related]
72. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
[TBL] [Abstract][Full Text] [Related]
73. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
74. rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.
Liu Y; Xu Z; Wang Y; Li X; Liu L; Chen L; Xin S; Xu D
PLoS One; 2014; 9(2):e89015. PubMed ID: 24586482
[TBL] [Abstract][Full Text] [Related]
75. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD
World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827
[TBL] [Abstract][Full Text] [Related]
76. Quantitative intrahepatic HBV cccDNA correlates with histological liver inflammation in chronic hepatitis B virus infection.
Liang LB; Zhu X; Yan LB; Du LY; Liu C; Liao J; Tang H
Int J Infect Dis; 2016 Nov; 52():77-82. PubMed ID: 27686728
[TBL] [Abstract][Full Text] [Related]
77. Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients.
Miyauchi T; Kanda T; Shinozaki M; Kamezaki H; Wu S; Nakamoto S; Kato K; Arai M; Mikami S; Sugiura N; Kimura M; Goto N; Imazeki F; Yokosuka O
Int J Med Sci; 2013; 10(6):647-52. PubMed ID: 23569428
[TBL] [Abstract][Full Text] [Related]
78. Differences in sequences between HBV-relaxed circular DNA and covalently closed circular DNA.
Rybicka M; Woziwodzka A; Romanowski T; Stalke P; Dręczewski M; Bielawski KP
Emerg Microbes Infect; 2017 Jun; 6(6):e55. PubMed ID: 28634352
[TBL] [Abstract][Full Text] [Related]
79. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
80. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B
Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
